IDEAYA Biosciences, Inc. — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/45e5b8f8-af48-4e63-a693-3f17460251e5/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-159.3M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-054533 |
| FY 2024 | $-327.0M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-022183 |
| FY 2023 | $-134.4M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-017093 |
| FY 2022 | $-62.5M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-006456 |
| FY 2021 | $-50.3M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-010922 |
| FY 2020 | $-35.3M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-014676 |
| FY 2019 | $-44.3M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-012501 |
| FY 2018 | $-36.4M | 2018-01-01 – 2018-12-31 | evidence 0001564590-20-012501 |
| FY 2017 | $-14.4M | 2017-01-01 – 2017-12-31 | evidence 0001564590-20-012501 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).